Rational design of partial agonists for the muscarinic M1 acetylcholine receptor

Journal of Medicinal Chemistry

Volumn 58, Issue 2, 2015, Pages 560-576

  Chen, Xinyu ^a,b   Klöckner, Jessika ^a   Holze, Janine ^c   Zimmermann, Cornelia ^c   Seemann, Wiebke K ^d   Schrage, Ramona ^c   Bock, Andreas ^a   Mohr, Klaus ^c   Tränkle, Christian ^c   Holzgrabe, Ulrike ^a   Decker, Michael ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

(6 (3 CHLOROPROPOXY)NAPHTHALEN 2 YL)METHANOL; (S) 1 ((6 (3 (2 ETHYL 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECAN 4 YL)PROPOXY)NAPHTHALEN 2 YL)METHYL) 8 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; (S) ETHYL 1 ((6 (3 (2 ETHYL 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECAN 4 YL)PROPOXY)NAPHTHALEN 2 YL)METHYL 8 FLUORO 4 OXO 1,4 DIHYDROQUINOLINE 3 CARBOXYLATE; (S) TERT BUTYL 2 ETHYL 4 (3 (6 (HYDROXYMETHYL)NAPHTHALEN 2 YLOXY)PROPYL) 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECANE 8 CARBOXYLATE; (S) TERT BUTYL 2 ETHYL 4 (3 (6 (IODOMETHYL)NAPHTHALEN 2 YLOXY)PROPYL) 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECANE 8 CARBOXYLATE; (S) TERT BUTYL 4 (3 (6 ((3 (ETHOXYCARBONYL) 8 FLUORO 4 OXOQUINOLIN 1(4H)YL)METHY)NAPHTHALEN 2 YLOXY)PROPYL) 2 ETHYL 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECANE 8 CARBOXYLATE; (S) TERT BUTYL 4 (3 (6 ((TERT BUTYLDIMETHYLSILYLOXY)METHYL)NAPHTHALEN 2 YLOXY)PROPYL) 2 ETHYL 3 OXO 1 THIA 4,8 DIAZASPIRO[4.5]DECANE 8 CARBOXYLATE; 6 (HYDROXYMETHYL)NAPHTHALEN 2 OL; ACETYLCHOLINE; IPEROXO; MUSCARINIC M1 RECEPTOR AGONIST; NAPHTHALENE DERIVATIVE; PARTIAL AGONIST; PILOCARPINE; TERT BUTYL((6 (3 CHLOROPROPOXY)NAPHTHALEN 2 YL)METHOXY)DIMETHYLSILANE; UNCLASSIFIED DRUG; MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR;

ALLOSTERISM; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; LIGAND BINDING; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; AGONISTS; ANIMAL; CRICETULUS; SYNTHESIS;

ANIMALS; CHO CELLS; CRICETULUS; DRUG DESIGN; MUSCARINIC AGONISTS; RECEPTOR, MUSCARINIC M1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921477284     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500860w     Document Type: Article

References (62)

1. Mohr, K.; Tränkle, C.; Kostenis, E.; Barocelli, E.; De Amici, M.; Holzgrabe, U. Rational design of dualsteric GPCR ligands: Quests and promise Br. J. Pharmacol. 2010, 159, 997-1008
2. Davie, B. J.; Christopoulos, A.; Scammells, P. J. Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits ACS Chem. Neurosci. 2013, 17, 1026-1048
3. Steinfeld, T.; Mammen, M.; Smith, J. A.; Wilson, R. D.; Jasper, J. R. A novel multivalent ligand that bridges the allosteric and orthosteric binding sites of the M2 muscarinic receptor Mol. Pharmacol. 2007, 72, 291-302
4. Antony, J.; Kellershohn, K.; Mohr-Andrae, M.; Kebig, A.; Prilla, S.; Muth, M.; Heller, E.; Disingrini, T.; Dallanoce, C.; Bertoni, S.; Schrobang, J.; Tränkle, C.; Kostenis, E.; Christopoulos, A.; Hoeltje, H.-D.; Barocelli, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity FASEB J. 2009, 23, 442-450
5. Bock, A.; Merten, N.; Schrage, R.; Dallanoce, C.; Bätz, J.; Klöckner, J.; Schmitz, J.; Matera, C.; Simon, K.; Kebig, A.; Peters, L.; Müller, A.; Schrobang-Ley, J.; Tränkle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. The allosteric vestibule of a seven transmembrance helical receptor controls G-Protein coupling Nature Commun. 2012, 3, 1044 10.1038/ncomms2028
6. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66
7. Bock, A.; Mohr, K. Dualsteric GPCR targeting and functional selectivity: the paradigmatic M(2) muscarinic acetylcholine receptor Drug Discovery Today: Technol. 2013, 10, 245-252
8. Bymaster, F. P.; McKinzie, D. L.; Felder, C. C.; Wess, J. Use of M1-M5 muscarinic receptor knockout mice as novel tools to declineate the physiological roles of the muscarinice cholinergic system Neurochem. Res. 2003, 28, 437-442
9. Lanzafame, A. A.; Christopoulos, A.; Mitchelson, F. Cellular signaling mechanisms for muscarinic acetylcholine receptors Recept. Channels 2003, 9, 241-260
10. Fisher, A. M1 muscarinic agonists target major hallmarks of Alzheimers disease-the pivotal role of brain M1 receptor Neurodegener. Dis. 2008, 5, 237-240
11. 2+ current and M-current by divergent signal transduction cascades J. Neurosci. 2006, 26, 11588-11598
12. Marino, M. J.; Rouse, S. T.; Levey, A. I.; Potter, L. T.; Conn, P. J. Activation of the genetically defined M1 muscarinic receptor potentiates N -methyl- d -aspartate (NMDA) receptor currents in hippocampal pyramidal cells Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 11465-11470
13. Fisher, A. Cholinergic treatments with emphasis on M1 muscarinic agonists as potential disease-modifying agents for Alzheimers disease Neurotherapeutics 2008, 5, 433-442
14. 1 muscarinic acetylcholine receptor allosteric modulators as potential therapeutic opportunities for treating Alzheimers disease Med. Chem. Commun. 2012, 3, 752-762
15. Anagnostaras, S. G.; Murphy, G. G.; Hamilton, S. E.; Mitchell, S. L.; Rahnama, N. P.; Nathanson, N. M.; Silva, A. J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice Nature Neurosci. 2003, 6, 51-58
16. Kruse, A. C.; Hu, J.; Pan, A. C.; Arlow, D. H.; Rosenbaum, D. M.; Rosemond, E.; Green, H. F.; Liu, T.; Chae, P. S.; Dror, R. O.; Shaw, D. E.; Weis, W. I.; Wess, J.; Kobilka, B. K. Structure and dynamics of the M3 muscarinic acetylcholine receptor Nature 2012, 482, 552-556
17. Haga, K.; Kruse, A. C.; Asada, H.; Yurugi-Kobayashi, T.; Shiroishi, M.; Zhang, C.; Weis, W. I.; Okada, T.; Kobilka, B. K.; Haga, T.; Kobayashi, T. Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist Nature 2012, 482, 547-551
18. Kruse, A. C.; Ring, A. M.; Manglik, A.; Hu, J.; Hu, K.; Eitel, K.; Hübner, H.; Pardon, E.; Valant, C.; Sexton, P. M.; Christopoulos, A.; Felder, C. C.; Gmeiner, P.; Steyaert, J.; Weis, W. I.; Garcia, K. C.; Wess, J.; Kobilka, B. K. Activation and allosteric modulation of a muscarinic acetylcholine receptor Nature 2013, 504, 101-106
19. Schrage, R.; Seemann, W. K.; Klöckner, J.; Dallanoce, C.; Racké, K.; Kostenis, E.; De Amici, M.; Holzgrabe, U.; Mohr, K. Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor Br. J. Pharmacol. 2013, 169, 357-370
20. Venkatakrishnan, A. J.; Deupi, X.; Lebon, G.; Tate, C. G.; Schertler, G. F.; Babu, M. M. Molecular signatures of G-protein-coupled receptors Nature 2013, 494, 185-194
21. Hulme, E. C.; Birdsall, N. J.; Buckley, N. J. Muscarinic receptor subtypes Annu. Rev. Pharmacol. Toxicol. 1990, 30, 633-673
22. Daval, S. B.; Valant, C.; Bonnet, D.; Kellenberger, E.; Hibert, M.; Galzi, J. L.; Ilien, B. Fluorescent derivatives of AC-42 to probe bitopic orthosteric/allosteric binding mechanisms on muscarinic M1 receptors J. Med. Chem. 2012, 55, 2125-2143
23. Daval, S. B.; Kellenberger, E.; Bonnet, D.; Utard, V.; Galzi, J. L.; Ilien, B. Exploration of the orthosteric/allosteric interface in human m1 muscarinic receptors by bitopic fluorescent ligands Mol. Pharmacol. 2013, 84, 71-85
24. Goodwin, J. A.; Hulme, E. C.; Langmead, C. J.; Tehan, B. G. Roof and floor of the muscarinic binding pocket: variations in the binding modes of orthosteric ligands Mol. Pharmacol. 2007, 72, 1484-1496
25. Gnagey, A. L.; Seldenberg, M.; Ellis, J. Site-directed mutagenesis reveals two epitopes involved in the subtype selectivity of the allosteric interactions of gallamine at muscarinic acetylcholine receptors Mol. Pharmacol. 1999, 56, 1245-1253
26. Dror, R. O.; Green, H. F.; Valant, C.; Borhani, D. W.; Valcourt, J. R.; Pan, A. C.; Arlow, D. H.; Canals, M.; Lane, J. R.; Rahmani, R.; Baell, J. B.; Sexton, P. M.; Christopoulos, A.; Shaw, D. E. Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs Nature 2013, 503, 295-299
27. 3H]scopolamine and acetylcholine at muscarinic receptor subtypes: identification of a second allosteric site Mol. Pharmacol. 2000, 58, 194-207
28. Lazareno, S.; Popham, A.; Birdsall, N. J. M. Analogs of WIN 62,577 define a second allosteric site on muscarinic receptors Mol. Pharmacol. 2002, 62, 1492-1505
29. Matera, C.; Flammini, L.; Quadri, M.; Vivo, V.; Ballabeni, V.; Holzgrabe, U.; Mohr, K.; De Amici, M.; Barocelli, E.; Bertoni, S.; Dallanoce, C. Bis(ammonio)alkane-type agonists of muscarinic acetylcholine receptors: synthesis, in vitro functional characterization, and in vivo evaluation of their analgesic activity Eur. J. Med. Chem. 2014, 75, 222-232
30. Bock, A.; Chirinda, B.; Krebs, F.; Messerer, R.; Bätz, J.; Muth, M.; Dallanoce, C.; Klingenthal, D.; Tränkle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. Dynamic ligand binding dictates partial agonism at a G protein-coupled receptor Nature Chem. Biol. 2014, 10, 18-20
31. January, B.; Seibold, A.; Whaley, B.; Hipkin, R. W.; Lin, D.; Schonbrunn, A.; Barber, R.; Clark, R. B. Beta2-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists J. Biol. Chem. 1997, 272, 23871-23879
32. Mailman, R. B.; Murthy, V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr. Pharm. Des. 2010, 16, 488-501
33. Kuduk, S. D.; Beshore, D. C. Novel M(1) allosteric ligands: a patent review Expert Opin. Ther. Pat. 2012, 22, 1385-1398
34. 1 muscarinic receptor J. Med. Chem. 2013, 56, 5151-5172
35. Yeatman, H. R.; Lane, J. R.; Choy, K. H.; Lambert, N. A.; Sexton, P. M.; Christopoulos, A.; Canals, M. Allosteric modulation of M1 muscarinic acetylcholine receptor internalization and subcellular trafficking J. Biol. Chem. 2014, 289, 15856-15866
36. 1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 15950-15955
37. 1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning J. Neurosci. 2009, 29, 14271-14286
38. Abdul-Ridha, A.; López, L.; Keov, P.; Thal, D. M.; Mistry, S. N.; Sexton, P. M.; Lane, J. R.; Canals, M.; Christopoulos, A. Molecular determinants of allosteric modulation at the M1 muscarinic acetylcholine receptor J. Biol. Chem. 2014, 289, 6067-6079
39. Fisher, A.; Bar-Ner, N.; Karton, Y. Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor. U.S. Patent 7,439,251, 2008.
40. 1 allosteric muscarinic receptor modulators ACS Med. Chem. Lett. 2010, 1, 263-267
41. Fisher, A. Cholinergic modulation of amyloid precursor protein processing with emphasis on M1 muscarinic receptor: Perspective and challenges in treatment of Alzheimers disease J. Neurochem. 2012, 120 (Suppl 1) 22-33
42. Schröder, R.; Janssen, N.; Schmidt, J.; Kebig, A.; Merten, N.; Hennen, S.; Müller, A.; Blättermann, S.; Mohr-Andrä, M.; Zahn, S.; Wenzel, J.; Smith, N. J.; Gomeza, J.; Drewke, C.; Milligan, G.; Mohr, K.; Kostenis, E. Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements Nature Biotechnol. 2010, 28, 943-949
43. Schröder, R.; Schmidt, J.; Blättermann, S.; Peters, L.; Janssen, N.; Grundmann, M.; Seemann, W.; Kaufel, D.; Merten, N.; Drewke, C.; Gomeza, J.; Milligan, G.; Mohr, K.; Kostenis, E. Applying label-free dynamic mass redistribution technology to frame signaling of G-protein-coupled receptors noninvasively in living cells Nature Protoc. 2011, 6, 1748-1760
44. Leyva, E.; Monreal, E.; Hernández, A. Synthesis of fluoro-4-hydroxyquinoline-3-carboxylic acids by the Gould-Jacobs reaction J. Fluor. Chem. 1999, 94, 7-10
45. Klöckner, J.; Schmitz, J.; Holzgrabe, U. Convergent, short synthesis of the muscarinic superagonist iperoxo Tetrahedron Lett. 2010, 51, 3470-3472
46. Walz, A. J.; Miller, M. J. Synthesis and biological activity of hydroxamic acid-derived vasopeptidase inhibitor analogues Org. Lett. 2002, 4, 2047-2050
47. Zhu, S.-F.; Song, X.-G.; Li, Y.; Cai, Y.; Zhou, Q.-L. Enantioselective copper-catalyzed intramolecular O-H insertion: an efficient approach to chiral 2-carboxy cyclic ethers J. Am. Chem. Soc. 2010, 132, 16374-16376
48. Nair, S. K.; Matthews, J. J.; Stephan, J. C.; Ma, C.; Dovalsantos, E. Z.; Grubbs, A. W.; Sach, N. W.; ten Hoeve, W.; Koster, H.; Flahive, E. J.; Tanis, S. P.; Renner, M.; van Wiltenburg, J. Novel synthesis of CP-734432, an EP4 agonist, using Sharpless asymmetric dihydroxylation Tetrahedron Lett. 2010, 51, 1451-1454
49. Henning, R.; Lattrell, R.; Hermann, J. G.; Leven, M. Synthesis and neuroleptic activity of a series of 1-[1-(benzo-1,4-dioxan-2-ylmethyl)-4-piperidinyl]benzimidazolone derivatives J. Med. Chem. 1987, 30, 814-819
50. Black, J. W.; Leff, P. Operational models of pharmacological agonism Proc. R. Soc. London B: Biol. Sci. 1983, 220, 141-162
51. Lazareno, S.; Birdsall, N. J. M. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G-protein-coupled receptors: Interaction of strychnine and acetylcholine at muscarinic receptors Mol. Pharmacol. 1995, 48, 362-378
52. Jakubík, J.; Bacáková, L.; El-Fakahany, E. E.; Tuček, S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors Mol. Pharmacol. 1997, 52, 172-179
53. De Amici, M.; Dallanoce, C.; Holzgrabe, U.; Tränkle, C.; Mohr, K. Allosteric ligands for G protein-coupled receptors: a novel strategy with attractive therapeutic opportunities Med. Res. Rev. 2010, 30, 463-549
54. Bock, A.; Kostenis, E.; Tränkle, C.; Lohse, M. J.; Mohr, K. Pilot the pulse: controlling the multiplicity of receptor dynamics Trends Pharmacol. Sci. 2014, 35, 630-638
55. De la Cruz, A.; Elguero, J.; Goya, P.; Martínez, A. Tautomerism and Acidity in 4-Quinolone-3-carboxylic Acid Derivatives Tetrahedron 1992, 29, 6135-6150
56. Fang, L.; Jumpertz, S.; Zhang, Y.; Appenroth, D.; Fleck, C.; Mohr, K.; Tränkle, C.; Decker, M. Hybrid molecules from xanomeline and tacrine: enhanced tacrine actions on cholinesterases and muscarinic M1 receptor J. Med. Chem. 2010, 53, 2094-2103
57. Nesterov, A.; Hong, M.; Hertel, C.; Jiao, P.; Brownell, L.; Cannon, E. Screening a plant extract library for inhibitors of cholecystokinin receptor CCK1 pathways J. Biomol. Screening 2010, 15, 518-527
58. Hennen, S.; Wang, H.; Peters, L.; Merten, N.; Simon, K.; Spinrath, A.; Blättermann, S.; Akkari, R.; Schrage, R.; Schröder, R.; Schulz, D.; Vermeiren, C.; Zimmermann, K.; Kehraus, S.; Drewke, C.; Pfeifer, A.; König, G. M.; Mohr, K.; Gillard, M.; Müller, C. E.; Lu, Q. R.; Gomeza, J.; Kostenis, E. Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist Sci. Signaling 2013, 6, ra93 10.1126/scisignal.2004350
59. Schröder, R.; Merten, N.; Mathiesen, J. M.; Martini, L.; Kruljac-Letunic, A.; Krop, F.; Blaukat, A.; Fang, Y.; Tran, E.; Ulven, T.; Drewke, C.; Whistler, J.; Pardo, L.; Gomeza, J.; Kostenis, E. The C-terminal tail of CRTH2 is a key molecular determinant that constrains Galphai and downstream signaling cascade activation J. Biol. Chem. 2009, 284, 1324-1336
60. De Blasi, A.; Oreilly, K.; Motulsky, H. J. Calculating receptor number from binding experiments using same compound as radioligand and competitor Trends Pharmacol. Sci. 1989, 10, 227-229
61. May, L. T.; Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 2007, 47, 1-51
62. Tränkle, C.; Weyand, O.; Voigtländer, U.; Mynett, A.; Lazareno, S.; Birdsall, N. J.; Mohr, K. Interactions of orthosteric and allosteric ligands with [3H]dimethyl-W84 at the common allosteric site of muscarinic M2 receptors Mol. Pharmacol. 2003, 64, 180-190